Changeflow GovPing Pharma & Drug Safety Soluble ENPP1 or ENPP3 Proteins and Uses Thereof
Routine Notice Added Final

Soluble ENPP1 or ENPP3 Proteins and Uses Thereof

Favicon for changeflow.com EPO Patent Bulletin - Biotech (C12N)
Published
Detected
Email

Summary

The European Patent Office published application EP4162036A1 for BioMarin Pharmaceutical Inc. and Yale University covering soluble ENPP1 or ENPP3 proteins and their uses. The patent application was published April 8, 2026 with A1 designation (first publication with European search report). The application designates all European contracting states including AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LI, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, and TR.

Published by EPO on changeflow.com . Detected, standardized, and enriched by GovPing. Review our methodology and editorial standards .

What changed

The European Patent Office published patent application EP4162036A1 filed by BioMarin Pharmaceutical Inc. and Yale University. The application covers soluble ENPP1 or ENPP3 proteins and their therapeutic uses, classified under IPC codes C12N 9/14, C12N 9/16, and A61K 38/46. The A1 publication indicates the European search report is included.\n\nThis publication establishes the patent's priority date and makes the technical disclosure publicly available. Competing pharmaceutical developers should review freedom-to-operate implications for any overlapping ENPP1/ENPP3 research programs. The patent designates all European contracting states, creating IP risk for those developing similar biopharmaceutical products in those jurisdictions.

Archived snapshot

Apr 18, 2026

GovPing captured this document from the original source. If the source has since changed or been removed, this is the text as it existed at that time.

← EPO Patent Bulletin

SOLUBLE ENPP1 OR ENPP3 PROTEINS AND USES THEREOF

Publication EP4162036A1 Kind: A1 Apr 08, 2026

Applicants

BioMarin Pharmaceutical Inc., Yale University

Inventors

CHENG, Zhiliang, BRADDOCK, Demetrios, STABACH, Paul, JUNGLES, Steven

IPC Classifications

C12N 9/14 20060101AFI20211217BHEP A61K 38/46 20060101ALI20211217BHEP C12N 9/16 20060101ALI20211217BHEP

Designated States

AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LI, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR

View original document →

Get daily alerts for EPO Patent Bulletin - Biotech (C12N)

Daily digest delivered to your inbox.

Free. Unsubscribe anytime.

About this page

What is GovPing?

Every important government, regulator, and court update from around the world. One place. Real-time. Free. Our mission

What's from the agency?

Source document text, dates, docket IDs, and authority are extracted directly from EPO.

What's AI-generated?

The summary, classification, recommended actions, deadlines, and penalty information are AI-generated from the original text and may contain errors. Always verify against the source document.

Last updated

Classification

Agency
EPO
Published
April 8th, 2026
Instrument
Notice
Legal weight
Binding
Stage
Final
Change scope
Minor
Document ID
EP4162036A1

Who this affects

Applies to
Pharmaceutical companies
Industry sector
3254 Pharmaceutical Manufacturing
Activity scope
Biotechnology patents Protein therapeutics
Geographic scope
European Union EU

Taxonomy

Primary area
Intellectual Property
Operational domain
Legal
Topics
Pharmaceuticals Healthcare

Get alerts for this source

We'll email you when EPO Patent Bulletin - Biotech (C12N) publishes new changes.

Free. Unsubscribe anytime.

You're subscribed!